Testing effectiveness (Phase 2)Study completedNCT01266369What this trial is testingMasitinib in Patients With Mastocytosis With Handicap and Bearing the D816V MutationWho this might be right forMastocytosis AB Science 21
Not applicableLooking for participantsNCT04557969What this trial is testingSurgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic AnalysisWho this might be right forGastric CancerGastric NeoplasmGastrointestinal Stromal Sarcoma+2 more National Cancer Institute (NCI) 400
Not applicableStudy completedNCT00336076What this trial is testingMolecular Mechanisms and Diagnosis of MastocytosisWho this might be right forMastocytosis University of Michigan 136
Testing effectiveness (Phase 2)Study completedNCT01395121What this trial is testingA Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has SpreadWho this might be right forMucosal Lentiginous MelanomaAcral Lentiginous Malignant Melanoma Institute of Cancer Research, United Kingdom 29
Testing effectiveness (Phase 2)Active Not RecruitingNCT03731260What this trial is testing(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic MastocytosisWho this might be right forIndolent Systemic Mastocytosis Blueprint Medicines Corporation 251
Large-scale testing (Phase 3)Study completedNCT02260505What this trial is testingEfficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)Who this might be right forGastrointestinal Stromal TumorsResected Gastrointestinal Stromal TumorsNon-metastatic+2 more Centre Leon Berard 136
Testing effectiveness (Phase 2)Study completedNCT02606097What this trial is testingRegorafenib in GIST With Secondary C-KIT Exon 17 MutationWho this might be right forGastrointestinal Stromal Tumour (GIST) Chang Gung Memorial Hospital 19
Testing effectiveness (Phase 2)UnknownNCT05821738What this trial is testingAvapritinib in CBF-AML With KIT MutationsWho this might be right forCore Binding Factor Acute Myeloid LeukemiaKIT Mutation-Related Tumors The First Affiliated Hospital of Soochow University 50
Not applicableStudy completedNCT05347745What this trial is testingTherascreen® KRAS RGQ PCR KitWho this might be right forColo-rectal Cancer QIAGEN Gaithersburg, Inc 219
Large-scale testing (Phase 3)Ended earlyNCT01280565What this trial is testingMasitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-KitWho this might be right forMetastatic Melanoma AB Science 134
Testing effectiveness (Phase 2)Looking for participantsNCT07559864What this trial is testingComparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard TreatmentWho this might be right forGIST - Gastrointestinal Stromal TumorKIT Gene Mutation Jian Li 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT06087263What this trial is testingPhase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.Who this might be right forGastrointestinal Stromal Tumors M.D. Anderson Cancer Center 3
Testing effectiveness (Phase 2)UnknownNCT01168050What this trial is testingEfficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.Who this might be right forMalignant Skin Melanoma T0Stage III MelanomaStage IV Melanoma+1 more Assistance Publique - Hôpitaux de Paris 25
Not applicableStudy completedNCT05410652What this trial is testingHelicobacter Pylori 23S rRNA/gyrA Gene Mutation Detection Kit (Fluorescence PCR Fusion Curve Method)Who this might be right forHelicobacter Pylori InfectionHelicobacter Pylori gyrA Levofloxacin Resistance MutationFecal Drug Resistance Gene Detection+1 more Nanjing First Hospital, Nanjing Medical University 1,176
Testing effectiveness (Phase 2)UnknownNCT02461849What this trial is testingPatients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib TherapyWho this might be right forAdvanced, Refractory Cancer Samsung Medical Center 14
Not applicableLooking for participantsNCT07264959What this trial is testingAn Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)Who this might be right forIndolent Systemic Mastocytosis Blueprint Medicines Corporation 150
Not applicableStudy completedNCT02503800What this trial is testingThe Significance of Blood-tryptase and c-Kit Mutation in Insect Venom ImmunotherapyWho this might be right forHypersensitivity, ImmediateInsect Bites and StingsMastocytosis Meir Medical Center 159
Testing effectiveness (Phase 2)Study completedNCT03580655What this trial is testing(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic MastocytosisWho this might be right forAdvanced Systemic MastocytosisAggressive Systemic MastocytosisSystemic Mastocytosis With an Associated Hematologic Neoplasm+1 more Blueprint Medicines Corporation 107
Not applicableWithdrawnNCT06116318What this trial is testingC-Kit Mutation as MRD in Acute Myeloid LeukemiaWho this might be right forC-KIT Mutation Institute of Hematology & Blood Diseases Hospital, China
Testing effectiveness (Phase 2)Study completedNCT02272998What this trial is testingPonatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.Who this might be right forMalignant Neoplasm Sameek Roychowdhury 22